Neuren Pharmaceuticals
Home
About Us
Company Overview
Company Values
Leadership Team
Corporate Directory
Product development
Product Development Pipeline
The science behind Neuren's products
Trofinetide (also known as NNZ-2566) in Rett Syndrome
Trofinetide (also known as NNZ-2566) in Fragile X Syndrome
NNZ-2591 in Phelan-McDermid syndrome
NNZ-2591 in Angelman syndrome
NNZ-2591 in Pitt Hopkins syndrome
Investor Information
Welcome
Share Price Information
Corporate Calendar
Shareholder Services
Corporate Governance
Analyst Coverage
Corporate Directory
News & Reports
ASX Announcements
Annual and Interim Reports
Scientific presentations
Investor presentations, audio, video
Email Alerts
Publications
Contact Us
Contact Us
Email Alerts
ASX Announcements
Annual and Interim Reports
Scientific presentations
Investor presentations, audio, video
Email Alerts
Publications
Home
>
News & Reports
>
ASX Announcements
Font Smaller
Font larger
Print Page
ASX Announcements
11-Jan-2021
European Commission grants 3 NNZ-2591 Orphan designations
7-Dec-2020
Notification of investor briefing webinar
7-Dec-2020
Neuren receives notice of positive opinion on all three Orphan designation applications for NNZ-2591
19-Nov-2020
Approval received for final stage of NNZ-2591 clinical trial
29-Oct-2020
Quarterly report and cash flow statement for Q3 2020
29-Sep-2020
Neuren requests Orphan designations for NNZ-2591 in Europe
22-Sep-2020
Neuren initiates manufacture of NNZ-2591 for Phase 2 trials
26-Aug-2020
Half-year Shareholder Update
26-Aug-2020
Half Yearly Report and Accounts
18-Aug-2020
Corporate presentation, 18 August 2020
11-Aug-2020
Change of Director's Interest Notice
7-Aug-2020
Appendix 2A
7-Aug-2020
Change of Director's Interest Notice
5-Aug-2020
Completion of Share Purchase Plan
30-Jul-2020
Appointment of CFO & Company Secretary
27-Jul-2020
Q2 2020 Activity Report and Cash Flow Report
14-Jul-2020
Final share buy-back notice - Appendix 3F
14-Jul-2020
Announcement of buy-back - Appendix 3C
14-Jul-2020
Scientific publications and presentations for trofinetide and NNZ-2591
13-Jul-2020
Appendix 3G
9-Jul-2020
Share Purchase Plan Offer Booklet
6-Jul-2020
Section 708A notice
6-Jul-2020
Appendix 2A
1-Jul-2020
Electing to receive SPP documents by e-mail
29-Jun-2020
Results of Meeting
29-Jun-2020
AGM Chairman's Address and CEO Presentation
29-Jun-2020
Proposed issue of Securities - NEU
29-Jun-2020
Neuren successfully completes $20m capital raising
25-Jun-2020
Trading Halt
16-Jun-2020
Temporary enrolment pause ended in Phase 3 trial in the US
2-Jun-2020
Change of Director's Interest Notice
1-Jun-2020
Change of Director's Interest Notice
29-May-2020
Final Director's Interest Notice
28-May-2020
Virtual AGM online guide
28-May-2020
Notice of Annual General Meeting/Proxy Form
27-May-2020
Neuren announces changes to leadership team
7-May-2020
Neuren commences first clinical trial for NNZ-2591
29-Apr-2020
Appendix 4G
29-Apr-2020
Annual Report 2019
17-Apr-2020
Appendix 4C - quarterly
17-Apr-2020
Q1 2020 Activity Report
6-Apr-2020
Corporate presentation, 6 April 2020
2-Apr-2020
First patent in Israel granted for trofinetide
26-Mar-2020
Change of Director's Interest Notice
26-Mar-2020
New international institutional shareholder acquires 14% of Neuren
24-Mar-2020
Change of Director's Interest Notice
24-Mar-2020
Temporary pause in new enrolments for LAVENDER trial in US
20-Mar-2020
Trading Halt
17-Mar-2020
Neuren to capture substantially greater value after Phase 3
10-Mar-2020
Additional information
6-Mar-2020
Compelling results for NNZ-2591 dose ranging study in Phelan-McDermid syndrome model
4-Mar-2020
Commentary on potential benefit to Neuren of RPD designation
4-Mar-2020
Rare Pediatric Disease designation received from FDA
26-Feb-2020
5 Orphan Drug programs and Rett in Phase 3 funded by partner
26-Feb-2020
Appendix 4E and 2019 full year accounts
19-Feb-2020
Update on trofinetide Phase 3 trial in Rett syndrome
28-Jan-2020
Appendix 4C - quarterly
12-Dec-2019
2019 year-end update and 2020 outlook
3-Dec-2019
Patent to 2034 granted in Europe for Neuren's NNZ-2591
31-Oct-2019
Phase 3 trial of trofinetide in Rett syndrome commences
18-Oct-2019
Neuren Corporate Presentation, October 2019
17-Oct-2019
Appendix 4C - quarterly
16-Oct-2019
FDA grants Orphan Drug designation for NNZ-2591 in Phelan-McDermid and Pitt Hopkins syndromes
16-Oct-2019
Pause in Trading
11-Oct-2019
FDA grants Orphan Drug Designation for NNZ-2591 in Angelman
20-Sep-2019
Neuren approaching key milestones in Q4 2019
28-Aug-2019
Neuren advances pipeline for neurodevelopmental disorders
28-Aug-2019
Half Yearly Report and Accounts
16-Aug-2019
New patent granted for Neuren's NNZ-2591 in Japan
31-Jul-2019
Appendix 4C - quarterly
29-Jul-2019
Neuren submits 3 NNZ-2591 Orphan Drug applications to FDA
16-Jul-2019
Neuren receives final payment from Lanstead Capital
28-May-2019
Results of Meeting
28-May-2019
Chairman's Address at 2019 Annual Meeting of Shareholders
17-May-2019
Validation for NNZ-2591 neurodevelopmental disorder pipeline
17-May-2019
NNZ-2591 positive effects in Pitt Hopkins syndrome model
17-May-2019
NNZ-2591 positive effects in Angelman syndrome model
30-Apr-2019
Appendix 4C - quarterly
29-Apr-2019
Notice of Annual General Meeting/Proxy Form
26-Apr-2019
Appendix 4G
26-Apr-2019
Annual Report to shareholders
26-Apr-2019
Update on development plan for NNZ-2591
28-Mar-2019
Neuren's Rett syndrome Phase 2 trial published in Neurology
27-Feb-2019
Fundamentals strong as Neuren advances neuroscience pipeline
27-Feb-2019
Preliminary Final Report and statutory accounts
18-Feb-2019
NNZ-2591 positive effects in Phelan-McDermid syndrome model
4-Feb-2019
Plans for Phase 3 trial in Rett syndrome
1-Feb-2019
Neuren retains ex-North America, appoints investment bank
31-Jan-2019
Appendix 4C - quarterly
3-Jan-2019
Final Director's Interest Notice
31-Dec-2018
Ceasing to be a substantial holder
18-Dec-2018
2018 Year-end Business Update
17-Dec-2018
Larry Glass to retire as a director and continue as CSO
2-Nov-2018
Presentation at AusBiotech Invest and Partnering 2018
31-Oct-2018
Appendix 4C - quarterly
26-Oct-2018
Trofinetide ex-North America exclusive negotiation period
17-Oct-2018
Neuren and ACADIA hold Rett syndrome SAB meeting
1-Oct-2018
Change of Director's Interest Notice
21-Sep-2018
FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID
6-Sep-2018
Investor presentation, 6 September 2018
31-Aug-2018
Half Yearly Report and Accounts
29-Aug-2018
Neuren and Lanstead agree to pause settlements for 120 days
22-Aug-2018
Appointment of auditor
22-Aug-2018
Neuren receives initial payment of US$10 million from ACADIA
16-Aug-2018
Change of Director's Interest Notice
15-Aug-2018
Change of Director's Interest Notice
7-Aug-2018
Investor update
7-Aug-2018
Neuren and ACADIA announce agreement for North America
31-Jul-2018
Appendix 4C - quarterly
9-Jul-2018
Initial Director's Interest Notice
5-Jul-2018
Initial Director's Interest Notice
5-Jul-2018
Initial Director's Interest Notice
4-Jul-2018
Neuren announces new appointments to the board of directors
18-Jun-2018
Results of Meeting
18-Jun-2018
Chairman's Address at 2018 Annual Shareholders' Meeting
30-May-2018
Change of Director's Interest Notice
30-May-2018
Final share buy-back notice - Appendix 3F
30-May-2018
Announcement of buy-back - Appendix 3C
23-May-2018
Notice under section 708A(5)(e) of the Corporations Act
23-May-2018
Appendix 3B
21-May-2018
Neuren announces investment and exclusive negotiation period
14-May-2018
Notice of Annual General Meeting/Proxy Form
8-May-2018
Appendix 4G
8-May-2018
Annual Report to shareholders
30-Apr-2018
Appendix 4C - quarterly
30-Apr-2018
First patent in Japan granted for Neuren's trofinetide
29-Mar-2018
Full Year Statutory Accounts
29-Mar-2018
Disclosure under Listing Rule 4.3D
9-Mar-2018
S&P DJ Indices Announces March Quarterly Rebalance
28-Feb-2018
Preliminary Final Report
30-Jan-2018
Appendix 4C - quarterly
29-Dec-2017
Final Director's Interest Notice
29-Dec-2017
Non-executive director retirement
27-Dec-2017
Change in substantial holding
5-Dec-2017
Neuren announces new US patent to be granted for NNZ-2591
16-Nov-2017
Consolidation/Split - NEU
16-Nov-2017
Notification under Listing Rule 7.20 of share reorganisation
26-Oct-2017
Appendix 4C - quarterly
13-Oct-2017
Neuren FDA meeting confirms Phase 3 plan for Rett syndrome
6-Oct-2017
Investor presentation, 6 October 2017
5-Oct-2017
Presentations and publication for Rett syndrome trials
30-Aug-2017
Change of Director's Interest Notice
30-Aug-2017
Change of Director's Interest Notice
30-Aug-2017
Change of Director's Interest Notice
29-Aug-2017
Notice under section 708A(5)(e) of the Corporations Act
29-Aug-2017
Appendix 3B
29-Aug-2017
Results of Meeting
24-Aug-2017
Neuren reports 2017 half-year results
24-Aug-2017
Half Yearly Report and Accounts
14-Aug-2017
Notice of special meeting of shareholders
27-Jul-2017
Appendix 4C - quarterly
21-Jul-2017
Becoming a substantial holder
20-Jul-2017
Neuren granted Type B Meeting with FDA for Rett syndrome
19-Jul-2017
Notice under section 708A(5)(e) of the Corporations Act
19-Jul-2017
Appendix 3B
13-Jul-2017
Notice under section 708A(5)(e) of the Corporations Act
13-Jul-2017
Appendix 3B
29-Jun-2017
Results of Meeting
29-Jun-2017
2017 AGM Chairman's Address
29-Jun-2017
Neuren secures funding for key activities for Rett syndrome
28-Jun-2017
Response to ASX Price Query
27-Jun-2017
Trading Halt
2-Jun-2017
Investor presentation, 2 June 2017
31-May-2017
Neuren announces grant of two new patents to 2032
29-May-2017
Notice of Annual General Meeting/Proxy Form
8-May-2017
Response to Appendix 4C Query
28-Apr-2017
Appendix 4C - quarterly
28-Apr-2017
Appendix 4G
28-Apr-2017
Annual Report to shareholders
4-Apr-2017
Neuren receives $1 million R&D Tax Incentive
3-Apr-2017
Investor presentation, 3 April 2017
30-Mar-2017
Full Year Statutory Accounts
22-Mar-2017
Neuren's Phase 2 trial of trofinetide demonstrates significant clinical benefit in pediatric Rett syndrome
17-Mar-2017
Trading Halt
10-Mar-2017
S&P DJ Indices Announces March Quarterly Rebalance
23-Feb-2017
Preliminary Final Report
2-Feb-2017
Investor presentation, 2 February 2017
31-Jan-2017
Appendix 4C - quarterly
30-Jan-2017
Neuren completes Phase 2 trial in pediatric Rett syndrome
6-Dec-2016
Results of Meeting
25-Nov-2016
Investor presentation, 25 November 2016
14-Nov-2016
Notice of special meeting of shareholders
14-Nov-2016
Neuren completes enrolment in Rett syndrome Phase 2 trial
31-Oct-2016
Appendix 4C - quarterly
28-Oct-2016
Neuren receives $0.9m from exercise of last expiring options
28-Oct-2016
Appendix 3B
9-Sep-2016
Change of Melbourne Registry Address Notification
31-Aug-2016
Change of Director's Interest Notice
31-Aug-2016
Appendix 3B
30-Aug-2016
Half Yearly Report and Accounts
25-Aug-2016
Neuren expands Phase 2 Rett syndrome pediatric trial
26-Jul-2016
Appendix 4C - quarterly
24-Jun-2016
Neuren presents at Rettsyndrome.org 2016 Research Symposium
22-Jun-2016
Grant of new patent for Autism Spectrum Disorders
31-May-2016
Results of Meeting
31-May-2016
Chairman's Address to Shareholders
16-May-2016
Change of Director's Interest Notice
13-May-2016
Presentation at 6th Annual TBI Conference, Washington DC
2-May-2016
Notice of Annual General Meeting/Proxy Form
29-Apr-2016
Appendix 4C - quarterly
26-Apr-2016
Neuren Shareholder Update
26-Apr-2016
Results of Phase 2 trial in moderate to severe TBI
22-Apr-2016
Trading Halt
18-Apr-2016
Appendix 4G
18-Apr-2016
Annual Report to shareholders
7-Apr-2016
First subject commences Neuren's Rett syndrome Phase 2 trial
25-Feb-2016
Neuren reports 2015 full-year financial results
25-Feb-2016
Appendix 4E and Financial Report 31 December 2015
29-Jan-2016
Appendix 4C - quarterly
11-Jan-2016
Neuren Investor Presentation, 11 January 2016
4-Jan-2016
Neuren Shareholder Update, January 2016
30-Dec-2015
Appendix 3B
7-Dec-2015
Trofinetide successful in Phase 2 trial in Fragile X
3-Dec-2015
Trading Halt
30-Nov-2015
Grant of composition patent in Europe for Neuren's NNZ-2591
17-Nov-2015
Corporations Act Notice
17-Nov-2015
Appendix 3B
9-Nov-2015
Shareholders provide further support for Rett syndrome
29-Oct-2015
Neuren completes enrolment in INTREPID clinical trial
21-Oct-2015
Appendix 4C - quarterly
13-Oct-2015
IRSF confirms financial support for Neuren's clinical trials
12-Oct-2015
New US patent covering use of trofinetide for Rett syndrome
29-Sep-2015
Neuren provides update on Fragile X and INTREPID trials
25-Aug-2015
Half Yearly Report and Accounts 30 June 2015
14-Aug-2015
trofinetide confirmed as INN for Neuren's NNZ-2566
13-Aug-2015
Neuren confirms orphan drug designations in Europe
31-Jul-2015
Investor presentation, 31 July 2015
30-Jul-2015
Appendix 4C - quarterly
29-Jul-2015
Neuren reports progress in orphan drug programs
1-Jun-2015
Appendix 3B
7-May-2015
Appendix 3B
28-Apr-2015
Results of Meeting
28-Apr-2015
Chairman's Address to Shareholders
22-Apr-2015
Appendix 3B
21-Apr-2015
Appendix 4C - quarterly
26-Mar-2015
Appendix 3B
25-Mar-2015
Notice of Annual General Meeting/Proxy Form
25-Mar-2015
Annual Report to shareholders
2-Mar-2015
Neuren receives response to request for Breakthrough Therapy
25-Feb-2015
Neuren reports 2014 full-year financial results
25-Feb-2015
Preliminary Final Report and 2014 full year accounts
16-Feb-2015
FDA grants Neuren Orphan Drug designation for Rett syndrome
6-Feb-2015
Appendix 3B
5-Feb-2015
Change of Director's Interest Notice
29-Jan-2015
Updated Share Trading Policy
28-Jan-2015
Neuren announces trofinetide as proposed INN for NNZ-2566
27-Jan-2015
Appendix 3B
22-Jan-2015
Appendix 4C - quarterly
8-Jan-2015
Investor Presentation, 8 January 2015
5-Jan-2015
Response to ASX Price Query
30-Dec-2014
Neuren submits Orphan Drug/Breakthrough Therapy applications
23-Dec-2014
Appendix 3B
3-Dec-2014
Appendix 3B
27-Nov-2014
Investor presentation, 27 November 2014
20-Nov-2014
Appendix 3B
12-Nov-2014
Neuren successful in Rett syndrome Phase 2 trial
10-Nov-2014
Trading Halt
28-Oct-2014
Appendix 3B
17-Oct-2014
Appendix 4C - quarterly
9-Oct-2014
Change of Director's Interest Notice
9-Oct-2014
Appendix 3B
24-Sep-2014
Appendix 3B
24-Sep-2014
Issue of long term incentives
24-Sep-2014
Neuren to release Rett Syndrome trial results in November
8-Sep-2014
Enrolment commences in Neuren's Concussion Phase 2 trial
4-Sep-2014
Investor presentation, 4 September 2014
29-Aug-2014
Appendix 3B
28-Aug-2014
Neuren reports 2014 half-year financial results
27-Aug-2014
Half Yearly Report and Accounts
15-Aug-2014
Appendix 3B
12-Aug-2014
Neuren advances NNZ-2591 towards IND application
22-Jul-2014
Appendix 3B
18-Jul-2014
Appendix 4C - quarterly
17-Jul-2014
US$3m increase to US Army grant and INTREPID outlook update
10-Jul-2014
Neuren receives ethics approval to start Concussion trial
26-Jun-2014
Neuren completes enrolment in Phase 2 trial in Rett Syndrome
25-Jun-2014
Appendix 3B
23-Jun-2014
Neuren appoints CMC expert to leadership team
4-Jun-2014
Neuren receives new US patent for NNZ-2591
3-Jun-2014
Appendix 3B
3-Jun-2014
Appendix 3B
30-May-2014
Appendix 3B
21-May-2014
Neuren presents at International Meeting for Autism Research
14-May-2014
Appendix 3B
30-Apr-2014
Appendix 3B
30-Apr-2014
AGM Results of Meeting
30-Apr-2014
Chairman's AGM Address to Shareholders
30-Apr-2014
Appendix 4C - quarterly
2-Apr-2014
Presentation at Morgans Emerging Companies Conference
27-Mar-2014
Notice of Annual General Meeting - Proxy Form
27-Mar-2014
Appendix 3B
27-Mar-2014
2013 Annual Report
7-Mar-2014
ZSP S and P DJ Indices Announces March Quarterly Rebalance
27-Feb-2014
Neuren reports financial results for 2013
27-Feb-2014
Preliminary Final Report and audited Financial Statements
21-Feb-2014
Appendix 3B
14-Feb-2014
Appendix 3B
28-Jan-2014
Neuren reports progress in NNZ-2566 clinical trial programs
15-Jan-2014
Appendix 3B
2-Jan-2014
Appendix 3B
29-Nov-2013
Appendix 3B
27-Nov-2013
Appendix 3B
27-Nov-2013
Neuren Share Purchase Plan raises $2 million
20-Nov-2013
Ceasing to be a substantial holder
19-Nov-2013
Investor presentation, 19 November 2013
15-Nov-2013
Appendix 3B
14-Nov-2013
Change in substantial holding
12-Nov-2013
Appendix 3B
6-Nov-2013
Change of Director's Interest Notice
4-Nov-2013
Share Purchase Plan record date
4-Nov-2013
SPP Certification
4-Nov-2013
Appendix 3B
31-Oct-2013
Becoming a substantial holder
30-Oct-2013
Share Purchase Plan offer documents
30-Oct-2013
Orphan drug designation from FDA for NNZ-2566 in Fragile X
28-Oct-2013
Section 708A(5)e Notice
28-Oct-2013
Appendix 3B
22-Oct-2013
Placement of $21.5m to accelerate execution of strategy
18-Oct-2013
Neuren receives Fast Track designation for Fragile X
18-Oct-2013
Trading Halt
10-Oct-2013
Appendix 3B
9-Oct-2013
Response to ASX Price Query
9-Oct-2013
Investor presentation
1-Oct-2013
Neuren data presented at Fragile X Foundation meeting
26-Sep-2013
Appendix 3B
19-Sep-2013
Change of Director's Interest Notice
11-Sep-2013
Appendix 3B
9-Sep-2013
Neuren opens new IND for NNZ-2566 in Fragile X Syndrome
4-Sep-2013
Final Director's Interest Notice
2-Sep-2013
Neuren announces changes to its leadership team
29-Aug-2013
Half Yearly Report and Accounts
5-Aug-2013
Notice under section 708A(5)(e) of the Corporations Act
5-Aug-2013
Response to social media commentary re Rett trial
5-Aug-2013
Trading Halt Request
5-Aug-2013
Trading Halt
30-Jul-2013
Investor presentation July 2013
30-Jul-2013
Appendix 3B Option Exercise
29-Jul-2013
Results in Fragile X Model with NNZ 2591
26-Jul-2013
Response to ASX Price Query
12-Jul-2013
Neuren receives two new patents
11-Jul-2013
Notice under section 708A(5)(e) of the Corporations Act
11-Jul-2013
Appendix 3B Option Exercise amended
11-Jul-2013
Appendix 3B Option Exercise
26-Jun-2013
Notice under section 708A(5)(e) of the Corporations Act
26-Jun-2013
Appendix 3B Option Exercise
25-Jun-2013
Response to ASX Price Query Letter
18-Jun-2013
Notice under section 708A(5)(e) of the Corporations Act
12-Jun-2013
Appendix 3B Option Exercise
5-Jun-2013
FDA Fast Track granted for NNZ2566 Rett program
29-May-2013
Change of Director's Interest Notice
29-May-2013
Appendix 3B Equity Performance Rights
29-May-2013
Appendix 3B Loan Funded Shares
29-May-2013
Notice under section 708A(5)(e) of the Corporations Act
24-May-2013
CFO appointment
22-May-2013
Final Director's Interest Notice
22-May-2013
Final Director's Interest Notice
22-May-2013
Appendix 3B Exercise of Options
22-May-2013
Lapse of Unlisted Options
22-May-2013
Change of Director's Interest Notice
22-May-2013
Change of Director's Interest Notice
21-May-2013
Investor Presentation May 2013
20-May-2013
Results of Meeting
20-May-2013
CEO Presentation to AGM
20-May-2013
Chairman's Address to AGM
15-May-2013
Response to ASX Price Query Letter
19-Apr-2013
Notice of Annual General Meeting/Proxy Form
15-Apr-2013
Shareholder Update
4-Apr-2013
Ceasing to be a substantial holder
28-Mar-2013
Annual Report to shareholders
28-Feb-2013
Preliminary Final Report
1-Feb-2013
Initial Director's Interest Notice
31-Jan-2013
Dr Richard Treagus joins Neuren Board
9-Jan-2013
Neuren appoints Nancy Jones SD Clinical & Medical Affairs
24-Dec-2012
Neuren IND open for Rett Phase II trial
20-Dec-2012
Appendix 3B
30-Nov-2012
Neuren TAP Conference presentation and Fragile X results
22-Nov-2012
Neuren completes Phase I NNZ2566 study/files Phase II IND
9-Nov-2012
Amended 2 - Change in substantial holding
9-Nov-2012
Amended Change in substantial holding
9-Nov-2012
Change in substantial holding
25-Oct-2012
Response to ASX Price Query
19-Oct-2012
NNZ2566 selected as Windhover Top 10 Neuroscience Project
30-Aug-2012
Half Yearly Report and Accounts
9-Aug-2012
Neuren appoints Joe Horrigan VP Clinical and Medical Affairs
7-Aug-2012
NNZ2566 Rationale in ASDs
6-Jul-2012
Neuren awarded Rett Syndrome trial grant
8-Jun-2012
Final Director`s Interest Notice
8-Jun-2012
Initial Director`s Interest Notice
31-May-2012
Results of Meeting
31-May-2012
CEO`s address to AGM
29-May-2012
Neuren announces cancer xenograft testing results
25-May-2012
Change in substantial holding
16-May-2012
Rett Syndrome pre-IND meeting held with FDA
2-May-2012
Notice under section 708A(5)(e) of the Corporations Act
27-Apr-2012
Appendix 3B (exercise of options)
27-Apr-2012
Notice of Annual General Meeting/Proxy Form
19-Apr-2012
Response to ASX Price Query
30-Mar-2012
Neuren 2011 Annual Report
8-Mar-2012
Initial Director`s Interest Notice
8-Mar-2012
Neuren appoints Bruce Hancox to board of directors
8-Mar-2012
Neuren presentation to Arrowhead TBI Conference
29-Feb-2012
Neuren 2011 Preliminary Final Report
22-Dec-2011
Neuren to proceed with oral NNZ2566 trial
12-Dec-2011
Change in substantial holding
9-Dec-2011
Response to ASX Price Query
21-Nov-2011
Neuren Completes Phase II trial Cohort 2
7-Nov-2011
Appendix 3B (exercise of options)
3-Nov-2011
Change in substantial holding
3-Nov-2011
Change in substantial holding
26-Oct-2011
Appendix 3B (amendment)
26-Oct-2011
Change of Director`s Interest Notice
26-Oct-2011
Change of Director`s Interest Notice
26-Oct-2011
Change of Director`s Interest Notice
26-Oct-2011
Change of Director`s Interest Notice
26-Oct-2011
Change of Director`s Interest Notice
26-Oct-2011
Appendix 3B
20-Oct-2011
Response to ASX Price Query
30-Aug-2011
Half Yearly Report and Accounts
17-Aug-2011
Becoming a substantial holder
16-Aug-2011
Becoming a substantial holder
16-Aug-2011
Notice under section 708A(5)(e) of the Corporations Act
16-Aug-2011
Appendix 3B
16-Aug-2011
Neuren places $3m of rights issue shortfall
29-Jul-2011
Appendix 4C - quarterly
27-Jul-2011
NEU Broker Presentation July 2011
22-Jul-2011
Neuren CEO presentation to Bioshares Biotech Summit
21-Jul-2011
Change of Director`s Interest Notice
21-Jul-2011
Change of Director`s Interest Notice
19-Jul-2011
Appendix 3B
19-Jul-2011
Results of Neuren Rights Issue
29-Jun-2011
Neuren Confirms Despatch of Rights Issue Offer Documents
28-Jun-2011
Appendix 3B
24-Jun-2011
CEO presentation to AusBiotech New York
20-Jun-2011
Rights Issue Eligible Shareholder Notice
20-Jun-2011
Change in substantial holding
15-Jun-2011
Rights Issue Notice to Foreign Shareholders
15-Jun-2011
Rights Issue Notice to Optionholders
15-Jun-2011
Rights Issue Notice under Section 708AA
15-Jun-2011
Appendix 3B (renounceable rights issue)
15-Jun-2011
Neuren Rights Issue Letter of Offer (Australian residents)
15-Jun-2011
Neuren Rights Issue Offer Document (NZ residents)
15-Jun-2011
Neuren announces Renounceable Rights Issue
6-Jun-2011
Notice under section 708A(5)(e) of the Corporations Act
6-Jun-2011
Neuren completes placement and converts remaining note
6-Jun-2011
Appendix 3B (options)
6-Jun-2011
Appendix 3B (shares)
3-Jun-2011
Notice under section 708A(5)(e) of the Corporations Act
3-Jun-2011
Appendix 3B
2-Jun-2011
Notice under section 708A(5)(e) of the Corporations Act
2-Jun-2011
Appendix 3B
31-May-2011
Results of Annual Meeting
31-May-2011
Results of Special Meeting
31-May-2011
Neuren CEO Presentation to AGM
20-May-2011
Neuren reduces outstanding convertible note principal
19-May-2011
Neuren`s Perseis selects lead antibodies
13-May-2011
Notice of Special Shareholders Meeting/Proxy Form
11-May-2011
Neuren Completes Phase II trial Cohort 1
6-May-2011
Notice under section 708A(5)(e) of the Corporations Act
6-May-2011
Appendix 3B
5-May-2011
Becoming a substantial holder
4-May-2011
Neuren Announces Private Placement and Rights Issue
2-May-2011
Trading Halt
29-Apr-2011
Notice of Annual General Meeting/Proxy Form
27-Apr-2011
Appendix 3B
20-Apr-2011
Notice under section 708A(5)(e) of the Corporations Act
20-Apr-2011
Appendix 3B
20-Apr-2011
Appendix 3B
31-Mar-2011
Annual Report to shareholders
23-Mar-2011
Appendix 3B
22-Mar-2011
Notice under section 708A(5)(e) of the Corporations Act
21-Mar-2011
Appendix 3B
21-Mar-2011
Appendix 3B
21-Mar-2011
Appendix 3B
21-Mar-2011
Results of Meeting
10-Mar-2011
Response to ASX Price Query
3-Mar-2011
Notice of Special Shareholders Meeting
28-Feb-2011
Preliminary Final Report
21-Feb-2011
Appendix 3B
18-Feb-2011
Notice under section 708A(5)(e) of the Corporations Act
18-Feb-2011
Appendix 3B
8-Feb-2011
Lapse of unquoted options
21-Jan-2011
Appendix 3B
21-Jan-2011
Appendix 3B (amended)
19-Jan-2011
Notice under section 708A(5)(e) of the Corporations Act
19-Jan-2011
Appendix 3B
19-Jan-2011
Appendix 3B
22-Dec-2010
Appendix 3B
20-Dec-2010
Notice under section 708A(5)(e) of the Corporations Act
20-Dec-2010
Securities Trading Policy
20-Dec-2010
Appendix 3B
20-Dec-2010
Appendix 3B
22-Nov-2010
Appendix 3B
19-Nov-2010
Notice under section 708A(5)(e) of the Corporations Act
19-Nov-2010
Appendix 3B
19-Nov-2010
Appendix 3B
18-Nov-2010
Neuren Initiates NNZ2566 Oral Formulation Development
16-Nov-2010
Neuren Completes Additional Phase I Study for TBI
27-Oct-2010
Appendix 3B
20-Oct-2010
Notice under section 708A(5)(e) of the Corporations Act
20-Oct-2010
Appendix 3B
20-Oct-2010
Appendix 3B
7-Oct-2010
Lapse of unquoted options
23-Sep-2010
Appendix 3B
21-Sep-2010
Notice under section 708A(5)(e) of the Corporations Act
21-Sep-2010
Appendix 3B
21-Sep-2010
Appendix 3B
26-Aug-2010
Half Yearly Report and Accounts
25-Aug-2010
Appendix 3B
20-Aug-2010
Notice under section 708A(5)(e) of the Corporations Act
20-Aug-2010
Appendix 3B
20-Aug-2010
Appendix 3B
23-Jul-2010
Appendix 3B
21-Jul-2010
Notice under section 708A(5)(e) of the Corporations Act
21-Jul-2010
SpringTree becomes a substantial shareholder
21-Jul-2010
Appendix 3B
21-Jul-2010
Appendix 3B
24-Jun-2010
Appendix 3B
21-Jun-2010
Notice under section 708A(5)(e) of the Corporations Act
21-Jun-2010
Appendix 3B (options)
21-Jun-2010
Appendix 3B (shares)
27-May-2010
Appendix 3B
25-May-2010
Results of Meeting
25-May-2010
CEO Presentation to AGM
21-May-2010
Notice under section 708A(5)(e) of the Corporations Act
21-May-2010
Appendix 3B
21-May-2010
Appendix 3B
6-May-2010
Neuren Starts Phase II Trial of NNZ2566
27-Apr-2010
Notice of Annual General Meeting/Proxy Form
23-Apr-2010
Appendix 3B (convertible note)
21-Apr-2010
Notice under section 708A(5)(e) of the Corporations Act
21-Apr-2010
Appendix 3B (options)
21-Apr-2010
Appendix 3B (shares)
6-Apr-2010
Lapse of unquoted options
30-Mar-2010
Annual Report to shareholders
25-Mar-2010
Appendix 3B - ESOP
24-Mar-2010
Appendix 3B (convertible note)
22-Mar-2010
Notice under section 708A(5)(e) of the Corporations Act
22-Mar-2010
Appendix 3B
22-Mar-2010
Appendix 3B
19-Mar-2010
Grant funding for TFF oncology program
3-Mar-2010
Trial of Second Neuren Drug Motiva to be Initiated
26-Feb-2010
Preliminary Final Report
22-Feb-2010
Appendix 3B (convertible note)
18-Feb-2010
Notice under section 708A(5)(e) of the Corporations Act
18-Feb-2010
Appendix 3B (options)
18-Feb-2010
Appendix 3B (shares)
12-Feb-2010
Ceasing to be a substantial holder
12-Feb-2010
Change in substantial holding
12-Feb-2010
Change in substantial holding
12-Feb-2010
Change in substantial holding
11-Feb-2010
Cato strategic partnership and appoints US CMO
20-Jan-2010
Appendix 3B
13-Jan-2010
Change in substantial holding
24-Dec-2009
Change of Director`s Interest Notice
23-Dec-2009
Notice under section 708A(5)(e) of the Corporations Act
23-Dec-2009
Appendix 3B (options)
23-Dec-2009
Appendix 3B (shares)
23-Dec-2009
Neuren Completes Shareholder Approved Funding
22-Dec-2009
Results of Special Shareholders Meeting
15-Dec-2009
Initial Director`s Interest Notice
4-Dec-2009
Notice under section 708A(5)(e) of the Corporations Act
4-Dec-2009
Appendix 3B
4-Dec-2009
Notice of Special Shareholders Meeting
25-Nov-2009
Dr John Holaday joins Neuren Board
18-Nov-2009
Appendix 3B (options)
18-Nov-2009
Notice under section 708A(5)(e) of the Corporations Act
18-Nov-2009
Appendix 3B (notes)
18-Nov-2009
Appendix 3B (shares)
18-Nov-2009
Neuren Arranges up to AU$7.8m in New Funding
18-Nov-2009
Reinstatement to Official Quotation
16-Nov-2009
Suspension from Official Quotation
12-Nov-2009
Trading Halt
25-Sep-2009
Notice under section 708A(5)(e) of the Corporations Act
25-Sep-2009
Appendix 3B
22-Sep-2009
Reponse to Price Query
31-Aug-2009
Half Year Report and Accounts
14-Aug-2009
Appendix 3B
14-Aug-2009
Neuren raises NZ$1 million through SPP
22-Jul-2009
Neuren SPP section 708A notice
21-Jul-2009
SPP NZ Certification
20-Jul-2009
Neuren NNZ-2566 Development Overview
20-Jul-2009
Neuren Share Purchase Plan
20-Jul-2009
Neuren Chairmans SPP Letter
15-Jul-2009
SPP terms update
10-Jul-2009
Neuren Share Purchase Plan
2-Jul-2009
Ceasing to be a substantial holder
1-Jul-2009
Neuren obtains further US$14m US Army funding
28-May-2009
Results of Meeting
28-May-2009
Presentation to AGM
28-May-2009
Chairman`s Address to Shareholders
28-Apr-2009
Notice of Annual General Meeting/Proxy Form
22-Apr-2009
Neuren Progresses Cancer Program
21-Apr-2009
Trading Halt
17-Apr-2009
Response to ASX Price Query
16-Apr-2009
Trading Halt
1-Apr-2009
Lapse of unquoted options
31-Mar-2009
Annual Report to shareholders
30-Mar-2009
Final Director`s Interest Notice
27-Feb-2009
Preliminary Final Report
21-Jan-2009
Neuren Strategy Update
20-Jan-2009
Respone to ASX price query
19-Jan-2009
Trading Halt
14-Jan-2009
Change of Director`s Interest Notice
24-Dec-2008
Neuren Announces Glypromate Trial Preliminary Results
10-Nov-2008
Phase 3 trial data collection completed
30-Sep-2008
Appendix 3B
30-Sep-2008
Change of Director`s Interest Notice
30-Sep-2008
Change of Director`s Interest Notice
30-Sep-2008
Neuren raises $2m through underwritten SPP
30-Sep-2008
Appendix 3B
4-Sep-2008
US Army to provide additional NNZ2566 trial funding
29-Aug-2008
Half Yearly Report and Accounts
28-Aug-2008
Results of Special Shareholders` Meeting
27-Aug-2008
Neuren extends SPP closing date
27-Aug-2008
Neuren signs cancer license and collaboration agreement
21-Aug-2008
NZ Securities Act certification for SPP
15-Aug-2008
Share Purchase Plan letter to eligible shareholders
15-Aug-2008
Notice under section 708A(5)(e) of the Corporations Act
12-Aug-2008
Change in substantial holding
12-Aug-2008
Notice of Special Meeting
6-Aug-2008
Neuren Share Purchase Plan
6-Aug-2008
Appendix 3B
6-Aug-2008
Neuren raises a minimum of $3 million
6-Aug-2008
Reinstatement to Official Quotation
4-Aug-2008
Voluntary Suspension extended
31-Jul-2008
Suspension from Official Quotation
29-Jul-2008
Trading Halt
21-Jul-2008
Glypromate and NNZ 2566 in Top 10 Neuroscience Projects
16-Jul-2008
NEU Completes Glypromate Phase 3 Recruitment
30-Jun-2008
Neuren to get early results from Glypromate trial
29-May-2008
Results of Meeting
29-May-2008
CEO presentation to AGM
26-May-2008
Response to ASX Query re: Appendix 4C
15-May-2008
Positive interim safety analysis for Glypromate
29-Apr-2008
Quarterly Update to Shareholders April 2008
29-Apr-2008
Notice of Annual General Meeting/Proxy Form
31-Mar-2008
Annual Report to shareholders
18-Mar-2008
Co-CEOs remuneration packages
29-Feb-2008
Appendix 4E Preliminary Final Report
26-Feb-2008
Appendix 3B
18-Feb-2008
Form 604
13-Feb-2008
Becoming a substantial holder
11-Feb-2008
Change of Director`s Interest Notice
11-Feb-2008
Change of Director`s Interest Notice
11-Feb-2008
Rights issue raises $7.1m and notes convert
11-Feb-2008
Substantial shareholder notice
7-Feb-2008
Change in substantial holding
7-Feb-2008
Appendix 3B - shares issued on conversion of notes
7-Feb-2008
Appendix 3B - allotment of rights issue underwriter shares
5-Feb-2008
Notice under section 708A(5)(e)
1-Feb-2008
Appendix 3B - allotment of rights issue shares
31-Jan-2008
Neuren Appendix 4C December 2007
31-Jan-2008
Results of Rights Issue
21-Jan-2008
US Department of Defense Approves NNZ2566 Funding
17-Jan-2008
Glypromate trial recruits 100th patient
9-Jan-2008
Neuren Confirms Despatch of Rights Issue Offer Documents
9-Jan-2008
Section 708AA Notice